The FDA disclosed a rejection letter for ivonescimab (Summit), citing multiple issues in its review. The publication of the rejection details comes as developers and investors sharpen scrutiny on trial endpoints, manufacturing, and benefit-risk framing in late-stage programs. Separately, Nuvalent’s buyout reportedly increased dividends for GSK, while other dealmaking and R&D pacts were also highlighted in the same market-focused update. Together, the items underscore how quickly pipeline progress can change once regulatory feedback becomes public. For biotech operators, the key immediate takeaway is the need to align remaining development work—such as next studies or protocol amendments—with the specific FDA objections described in the agency correspondence.
Get the Daily Brief